Search Bar & Filters
Found 51 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the climacteric period, which includes physical, hormonal, and emotional changes that can affect a womans quality of life during menopause. The study aims to understand how cultural and ethnic backgrounds influence womens experiences and quality of life during this stage. It also evaluates healthcare professionals knowledge and attitudes about menopause to identify gaps and improve care in Primary Care centers in Tarragona. The research has two parts a quantitative phase where healthcare professionals such as nurses and physicians complete an online survey assessing their knowledge and attitudes about menopause, diet, and physical activity and a qualitative phase involving in-depth interviews with women aged 40 to 65 from diverse sociocultural and ethnic backgrounds to explore their personal experiences during menopause. Data from both phases will be combined to help design better community nursing interventions. Participants in the qualitative phase will take part in individual semi-structured interviews to share their perceptions and lived experiences. Healthcare professionals will complete an anonymous electronic questionnaire. Researchers will analyze responses using statistics and thematic analysis to understand knowledge levels and womens experiences. The study follows ethical guidelines and aims to improve health promotion and equity for women during the climacteric stage. The overall study duration extends until 2030, with key completion milestones in 2028.
Actively Recruiting
Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.
Actively Recruiting
Researchers are evaluating treatments for advanced HRD-positive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, and clear cell carcinoma of the ovary in patients who have no residual tumor after primary tumor debulking. This phase II, multicenter, randomized, open-label study compares the recurrence-free survival of patients receiving either 3 cycles of carboplatin plus paclitaxel followed by maintenance therapy with niraparib or 6 cycles of the same chemotherapy plus niraparib maintenance. The study includes patients with specific disease stages FIGO IIIA to IV and uses genetic testing to stratify patients based on tumor characteristics.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating ALE.P03 monotherapy in adults with selected advanced or metastatic Claudin-1 positive CLDN1 solid tumors, including colorectal cancer, intrahepatic cholangiocarcinoma, squamous non-small cell lung cancer, urothelial carcinoma, and cervical squamous cell carcinoma. The study includes Phase I dose escalation to determine the maximum tolerated dose and recommended dose for expansion, followed by Phase II to assess the recommended Phase II dose. The purpose is to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of ALE.P03. Participants will receive ALE.P03 through intravenous infusion. In Phase I dose escalation, the dose is gradually increased until the maximum tolerated dose or a safe recommended dose is identified. In Phase I dose expansion, patients receive the safe recommended dose to confirm the recommended Phase II dose. In Phase II, participants receive ALE.P03 at the recommended Phase II dose or according to the dosing schedule after the expansion phase. Throughout the study, patients will undergo assessments including monitoring for dose limiting toxicities, adverse events, overall and duration of response, disease control rate, and survival outcomes up to four years. Blood samples will be collected for detailed pharmacokinetic and antibody analyses from treatment initiation until the end of treatment. Safety follow-up occurs up to 30 days after the last dose, with long-term monitoring extending up to four years. The study evaluates both clinical outcomes and biological measures to understand the effects of ALE.P03.
Actively Recruiting
Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.
Actively Recruiting
Researchers are investigating whether using artificial intelligence AI to guide monitoring and timing of ovulation trigger in women undergoing ovarian stimulation for in vitro fertilization IVF can achieve clinical outcomes similar to traditional physician-led decisions. This trial aims to compare AI-assisted decision-making with routine clinical management to optimize the number of eggs retrieved, improve workflow efficiency, and reduce clinical workload, especially weekend procedures. Participants will be randomly assigned to one of two groups one where trigger decisions are made by the physician assisted by the AI software called STIMAI, and the other where trigger timing is determined by the physician alone based on clinical judgement. The AI software analyzes patient data to predict the optimal trigger day, offering options for triggering today or tomorrow, while the physician makes the final decision. The study focuses on individualized treatment to improve outcomes and scheduling. During the study, participants will undergo controlled ovarian stimulation with regular monitoring including ultrasounds. Researchers will measure the number of mature eggs retrieved about 34-36 hours after ovulation trigger, as well as other outcomes like follicle counts, length of stimulation, and number of clinic visits. The trial also tracks spontaneous ovulation and the distribution of retrieval procedures throughout the week. Participation will last through the stimulation cycle until egg retrieval, with assessments of both clinical results and process efficiency.
Actively Recruiting
Researchers are studying breast cancer patients who have a positive sentinel lymph node after receiving neoadjuvant systemic treatment. The trial evaluates whether axillary radiotherapy ART reduces the risk of lymphedema compared to axillary lymph node dissection ALND in these patients. The study also examines recurrence and overall survival rates, as well as quality of life. This is a prospective, randomized, open-label, parallel group, multicenter study involving approximately 820 patients over 5 years. Participants are divided into two groups one receives axillary radiotherapy without lymphadenectomy, including radiation to levels I and II axilla, level III, supraclavicular area, and possibly the internal mammary chain the other group undergoes axillary lymph node dissection plus radiotherapy to level III, supraclavicular area, and possibly the internal mammary chain. Patients are stratified by neoadjuvant treatment type chemotherapy or hormone therapy. A pilot phase with the first 200 patients has been completed, and interim analysis will be performed. During the study, participants undergo evaluations including imaging by ultrasound or MRI to assess axillary response after neoadjuvant therapy. Researchers will track disease-free survival up to 5 years, overall survival up to 5 years, and incidence of lymphedema up to 3 years after surgery. Quality of life and safety outcomes will also be monitored. The study aims to provide data on whether avoiding lymphadenectomy is a viable option for patients responding well to neoadjuvant treatment.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of sovateltide, a new drug candidate, in treating patients with acute cerebral ischemic stroke. This type of stroke occurs when a blood clot blocks blood flow to the brain, causing damage to brain cells. The study builds on earlier clinical trials in India that showed promising results in improving neurological function and recovery with sovateltide, encouraging further testing in the United States and other countries. The trial compares sovateltide combined with standard care against a placebo normal saline plus standard care. Participants will receive three intravenous doses of sovateltide or placebo on days 1, 3, and 6 after stroke onset. Each dose is given as a one-minute IV bolus within 24 hours of stroke symptoms beginning. The study is randomized, double-blind, and placebo-controlled to rigorously assess the treatments impact. Participants will be monitored for 90 days after receiving treatment. Researchers will use several scales to evaluate recovery, including the modified Rankin Scale to measure disability, the National Institutes of Health Stroke Scale for neurological function, and the Barthel Index for daily living activities. Quality of life assessments and cognitive tests will also be done. Safety is closely watched for any adverse events or complications during the study period. The total participation time is about three months following treatment.
Actively Recruiting
Researchers are evaluating whether adding Quizartinib to the combination of Venetoclax and Azacytidine improves overall survival compared to Venetoclax and Azacytidine alone in adults with newly diagnosed acute myeloid leukemia AML who are not suitable for standard induction chemotherapy due to age, other health conditions, or risk factors. This Phase III trial will randomize participants to compare the two treatment regimens. Participants will be assigned to one of two groups the experimental group will receive Azacytidine as a subcutaneous injection daily on days 1 to 7 of each 28-day cycle, Venetoclax orally daily on days 1 to 7, and Quizartinib orally on days 8 to 21 with dose adjusted by FLT3-ITD mutation status. The standard group will receive Azacytidine daily on days 1 to 7 and Venetoclax daily for 28 days in each 28-day cycle. Treatment continues until disease progression, unacceptable side effects, withdrawal, or other protocol-defined reasons. During the study, participants will have regular clinical visits and follow-up assessments, with survival data collected every three months for two years after the last participant finishes treatment. Researchers will monitor overall survival over four years as the primary outcome, along with event-free survival and complete response rates. Safety and treatment effects will be tracked throughout the study period.
1-10 of 51
1